Share the post "Pfizer : Q4 2024 Financial Quarterly Report : YoY Sales Down 4.54 %, QoQ Up 1.23 %"
Highlights
- Sales over the Year and quarter: The company’s sales declined by -4.54 % over the year, substantial increase in net sales/revenue by 1.23 %.
- Income over the Year and quarter: There has been either a marginal increase or a decline in other income over the past year which is 139.42 %. Marginal increase in other income during this quarter, up by 109.57%.
- Profit over the Year and quarter: Significant improvement in profitability for Pfizer Ltd.,. Notable increase of 37.96 % in net profit Year to Year, Pfizer Ltd.,’s profitability increased by 37.61 % in this quarter.
- EPS over the Year and quarter: EPS declined by -21.21 % Year to Year. EPS decreased by -17.66 % in previous quarter. Analysis needed for shareholder value.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 572.64 Cr | Rs. 539.97 Cr | Rs. 546.63 Cr | + 1.23 % | -4.54 % |
| Expenses | Rs. 390.77 Cr | Rs. 387.42 Cr | Rs. 357.2 Cr | -7.8 % | -8.59 % |
| Operating Profit | Rs. 181.87 Cr | Rs. 152.55 Cr | Rs. 189.43 Cr | + 24.18 % | + 4.16 % |
| OPM % | 31.76 % | 28.25 % | 34.65 % | + 6.4 % | + 2.89 % |
| Other Income | Rs. 31.38 Cr | Rs. 35.85 Cr | Rs. 75.13 Cr | + 109.57 % | + 139.42 % |
| Interest | Rs. 2.53 Cr | Rs. 2.86 Cr | Rs. 6.95 Cr | + 143.01 % | + 174.7 % |
| Depreciation | Rs. 26.41 Cr | Rs. 17.55 Cr | Rs. 13.75 Cr | -21.65 % | -47.94 % |
| Profit before tax | Rs. 184.31 Cr | Rs. 167.99 Cr | Rs. 243.86 Cr | + 45.16 % | + 32.31 % |
| Tax % | 21.29 % | 26.12 % | 26.65 % | + 0.53 % | + 5.36 % |
| Net Profit | Rs. 129.65 Cr | Rs. 129.98 Cr | Rs. 178.86 Cr | + 37.61 % | + 37.96 % |
| EPS in Rs | Rs. 28.34 | Rs. 27.12 | Rs. 22.33 | -17.66 % | -21.21 % |
Today, we’re looking at Pfizer Ltd.,’s financial performance for the Q4(Mar 2024).Starting with the top line, the company reported a significant year-over-year sales decline of -4.54 %. However, it did see a marginal increase of 1.23 % from the previous quarter. Expenses decreased slightly by -7.8 % quarter-on-quarter, aligning with the annual decline of -8.59 %. Operating profit, while up 4.16 % compared to last year, faced a quarter-on-quarter increase of 24.18 %, signaling a short-term expansion in margins.
The Operating Profit Margin (OPM) % echoes this narrative, showing resilience on an annual basis with an increase of 2.89 %, but an expansion of 6.4 % sequentially. Other income rose by 109.57 % compared to the last quarter, despite an annual growth of 139.42 %. Interest expenses surged remarkably by 143.01 % from the previous quarter, yet the year-over-year increase remains at a moderate 174.7 %. Depreciation costs fell by -21.65 % quarter-on-quarter, yet on an annual scale, they experienced a reduction of -47.94 %. Profit before tax grew annually by 32.31 % but saw an increase from the preceding quarter by 45.16 %.
Tax expenses as a percentage of profits increased slightly by 5.36 % compared to last year, with a more notable quarter-on-quarter increase of 0.53 %. Net profit rose by 37.96 % year-on-year but experienced a 37.61 % expansion from the last quarter. And finally, Earnings Per Share (EPS) displayed an annual downturn of -21.21 % but a quarterly fall of -17.66 %. In summary, Pfizer Ltd.,’s annual performance indicates steady growth, although the quarter-on-quarter figures suggest some areas may require strategic attention.
| Metrics | Previous Year | Previous Quarter | Current Quarter | Quarter to Quarter Difference | Year to Year Difference |
|---|---|---|---|---|---|
| Sales | Rs. 572.64 Cr | Rs. 539.97 Cr | Rs. 546.63 Cr | + 1.23 % | -4.54 % |
| Expenses | Rs. 390.77 Cr | Rs. 387.42 Cr | Rs. 357.2 Cr | -7.8 % | -8.59 % |
| Operating Profit | Rs. 181.87 Cr | Rs. 152.55 Cr | Rs. 189.43 Cr | + 24.18 % | + 4.16 % |
| Net Profit | Rs. 129.65 Cr | Rs. 129.98 Cr | Rs. 178.86 Cr | + 37.61 % | + 37.96 % |
| EPS in Rs | Rs. 28.34 | Rs. 27.12 | Rs. 22.33 | -17.66 % | -21.21 % |
In reviewing Pfizer Ltd.,’s 2024(Q4) financial snapshot, key trends emerge, shedding light on the company’s performance.Sales experienced a decrease of -4.54 % year-on-year, however, there was a minor increase of 1.23 % from the previous quarter. Expenses decreased by -8.59 % compared to the previous year, with a decrease of -7.8 % quarter-on-quarter. Operating Profit surged by 4.16 % annually, and saw a 24.18 % increase from the last quarter.
Net Profit showed yearly increase of 37.96 %, and experienced a 37.61 % increase from the previous quarter. Earnings Per Share (EPS) fell by -21.21 % annually, however dipped by -17.66 % compared to the last quarter. In essence, while Pfizer Ltd., exhibits strong annual growth indicators, short-term improvements suggest the potential for recovery and the importance of strategic adjustments to counter market challenges effectively. That’s all for now in the financial sector.
3
3-Year Profit
5
5-Year Profit
10
10-Year Profit
5,830
Current Price
26,699
Market Cap
The company associated with BSE code 500680 presents a financial narrative of mixed fortunes. Over a five-year period, the company achieved a profit of 5 percents, which subsequently rose to 3 percents over the three years that followed. Yet, despite this initial growth, the company now faces a troubling trailing twelve-month (TTM) profit loss of 8 percents. What’s particularly striking is the company’s complete absence of reported sales across all analyzed periods, which brings into question the viability of its revenue generation strategies and long-term business sustainability. Moreover, stock prices have been highly volatile, reflecting the company’s uncertain future. While the stock was valued at 12 percents over the last five years, it has recently dropped to 40 percents, underscoring a rapid decline in market confidence. Over the longer ten-year period, the stock price was at 13 percents, illustrating a pattern of fluctuating performance that could pose risks for potential investors.
The company has a market capitalization of ₹26,699 crore and is currently trading at a stock price of ₹5,830. Over time, the stock has fluctuated between the historical highs and lows of ₹6,453 / 3,831, reflecting the market's volatility. With a Price-to-Earnings (P/E) ratio of 174, the stock appears highly valued, indicating that investors are willing to pay a premium for its earnings potential. The company's book value per share stands at ₹302, showcasing the underlying asset value. Additionally, the dividend yield is 0.60%, suggesting that the company offers shareholders a moderate return on their investment in the form of dividends. The Return on Capital Employed (ROCE) is 27.2%, indicating the efficiency with which the company generates profit from its capital. Meanwhile, the Return on Equity (ROE) is 19.8%, highlighting the profitability relative to shareholder equity. Despite these figures, the company maintains a very low debt-to-equity ratio of 0.00, signaling minimal leverage. It also reports a net cash flow of ₹63.7 crore, reflecting the company's ability to generate cash. The Piotroski score is 8.00, a measure of the company's financial strength, while the Graham Number estimates the intrinsic value of the stock at ₹826. The Price-to-Book (P/B) ratio of 19.3 further suggests that the stock is trading at a premium relative to its book value, potentially reflecting positive market sentiment or expectations of future growth.
